Goldman G, Welbourn R, Alexander S, Klausner J M, Wiles M, Valeri C R, Shepro D, Hechtman H B
Department of Surgery, Brigham and Women's Hospital, Boston, Mass. 02115.
Surgery. 1991 Apr;109(4):533-8.
In vitro studies show that the cytoskeleton of the microvascular barrier moderates polymorphonuclear leukocyte (PMN) diapedesis and the transport of macromolecules. This in vivo study tests indirectly whether the cytoskeleton of the pulmonary microvasculature responds similarly to agents known to reorganize the cytoskeleton to alter diapedesis and permeability in vitro. One of four agents, saline solution, cytochalasin B (which promotes actin microfilament disassembly), leukotriene (LT) B4 (PMN chemoattractant), or phalloidin (which promotes and stabilizes F-actin polymerization) was introduced into the bronchus of the anterior segment of the left lung of anesthetized rats (n = 152) through a tracheostomy and fine-bore cannula. Twenty minutes later, saline solution, cytochalasin B, LTB4, or phalloidin was similarly introduced. PMN accumulations (x 10(4) cells/ml), protein concentration in bronchoalveolar lavage fluid, and lung wet/dry weight ratios were measured 3 hours later. When the initial and secondary treatments were saline solution, PMN accumulations were 3 +/- 1 cells/ml and the protein level was 274 +/- 48 micrograms/ml. Secondary treatment of the saline-treated group with cytochalasin B or LTB4 led to increases in PMN to 18 +/- 2 and 9 +/- 2 cells/ml and protein to 960 +/- 50 and 840 +/- 40 micrograms/ml (p less than 0.05); secondary treatment with phalloidin was similar to that with saline solution. With saline solution used for both treatments, the wet/dry ratio was 3.4 +/- 0.2. Primary saline solution and secondary treatments with either cytochalasin B or LTB4 led to a similar increase in wet/dry ratios to 3.9 +/- 0.1 (p less than 0.05), whereas phalloidin was without effect (3.5 +/- 0.3). Initial cytochalasin B treatment followed by LTB4 led to increased PMN diapedesis (43 +/- 6 cells/ml and wet/dry ratio 4.3 +/- 0.2) (p less than 0.05). Secondary phalloidin treatment attenuated the cytochalasin B effect with counts of 12 +/- 2 PMN/ml, protein levels of 460 +/- 30 micrograms/ml, and a lower wet/dry ratio of 3.7 +/- 0.1 (p less than 0.05). Even more striking, phalloidin as initial treatment further reduced the cytochalasin B effect to 7 +/- 1 PMN/ml, whereas protein level was 490 +/- 60 micrograms/ml and wet/dry ratio was 3.5 +/- 0.1 (p less than 0.05). Further, phalloidin, given initially, attenuated the effect of secondary treatment with LTB4, resulting in fewer cells (4 +/- 2 PMN/ml), a lower wet/dry ratio (3.4 +/- 0.1), and protein level of 650 +/- 20 micrograms/ml (p less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)
体外研究表明,微血管屏障的细胞骨架可调节多形核白细胞(PMN)的渗出及大分子的转运。本体内研究间接测试肺微血管的细胞骨架对已知能在体外重组细胞骨架以改变渗出和通透性的药物是否有类似反应。将四种药物之一,即盐溶液、细胞松弛素B(促进肌动蛋白微丝解聚)、白三烯(LT)B4(PMN趋化因子)或鬼笔环肽(促进并稳定F - 肌动蛋白聚合),通过气管切开术和细孔插管引入麻醉大鼠(n = 152)左肺前段支气管。20分钟后,同样引入盐溶液、细胞松弛素B、LTB4或鬼笔环肽。3小时后测量PMN积聚量(×10⁴细胞/毫升)、支气管肺泡灌洗液中的蛋白质浓度以及肺湿/干重比。当初始和二次处理均为盐溶液时,PMN积聚量为3±1细胞/毫升,蛋白质水平为274±48微克/毫升。用细胞松弛素B或LTB4对盐溶液处理组进行二次处理后,PMN增加至18±2和9±2细胞/毫升,蛋白质增加至960±50和840±40微克/毫升(p<0.05);用鬼笔环肽进行二次处理与用盐溶液处理相似。两次处理均用盐溶液时,湿/干比为3.4±0.2。初始用盐溶液,二次用细胞松弛素B或LTB4处理导致湿/干比类似增加至3.9±0.1(p<0.05),而鬼笔环肽无作用(3.5±0.3)。初始用细胞松弛素B处理后再用LTB4导致PMN渗出增加(43±6细胞/毫升,湿/干比4.3±0.2)(p<0.05)。二次用鬼笔环肽处理减弱了细胞松弛素B的作用,PMN计数为12±2/毫升,蛋白质水平为460±30微克/毫升,湿/干比降低至3.7±0.1(p<0.05)。更显著的是,初始用鬼笔环肽处理进一步将细胞松弛素B的作用降低至7±1 PMN/毫升,而蛋白质水平为490±60微克/毫升,湿/干比为3.5±0.1(p<0.05)。此外,初始给予鬼笔环肽减弱了二次用LTB4处理的作用,导致细胞减少(4±2 PMN/毫升),湿/干比降低(3.4±0.1),蛋白质水平为650±20微克/毫升(p<0.05)。(摘要截短至400字)